Download PDF
Gastroenterologie up2date 2006; 2(3): 233-250
DOI: 10.1055/s-2006-944786
Neuroendokrine Tumoren des Gastrointestinaltraktes
© Georg Thieme Verlag KG Stuttgart · New York

Neuroendokrine Tumoren des Gastrointestinaltraktes

Ursula  Plöckinger
Further Information

Publication History

Publication Date:
20 September 2006 (online)

Also available at
    Permissions and Reprints All articles of this category

Updated by:

Neuroendokrine Neoplasien des gastroenteropankreatischen SystemsGastroenterologie up2date 2017; 13(02): 139-153
DOI: 10.1055/s-0043-107261

Kernaussagen

Klassifikation

Gastrointestinale neuroendokrine Tumoren werden als funktionelle bzw. nichtfunktionelle Tumoren sowie nach Lokalisation und Proliferationsverhalten klassifiziert.

Die korrekte Klassifikation entscheidet über den zu wählenden Therapieansatz.

Diagnostik

Die Diagnose funktioneller neuroendokriner Tumor erfordert den Nachweis der autonomen Hormonsekretion.

Zur Lokalisationsdiagnostik werden Ultraschall, CT, MRT und Somatostatin-Rezeptor-Szintigraphie eingesetzt. Die Lokalisation kleiner Primärtumoren erfordert invasive Verfahren wie endoskopischen oder intraoperativen Ultraschall.

Therapie

Bei lokalisierter Erkrankung ist die Operation die Therapie der Wahl.

Ist die Erkrankung ausgedehnt, kommen neben symptomatischen Therapien die Biotherapie und/oder eine Chemotherapie in Betracht.

Zytoreduktive Verfahren (Chemoembolisation, Thermo- oder Kryoablation, palliative operative Therapie von Lebermetastasen) und die Radiorezeptortherapie gewinnen an Bedeutung, auch wenn die Datenlage noch keine abschließende Beurteilung der Effektivität dieser Therapien erlaubt.

Literatur

  • 1 Moertel C G. Karnofsky memorial lecture. An odyssey in the land of small tumors.  J Clin Oncol. 1987;  5 1502-1522
    PubMedGoogle Scholar
  • 2 Modlin I M, Lye K D. et al . A 5-decade analysis of 13,715 carcinoid tumors.  Cancer. 2003;  97 934-959
    CrossrefPubMedGoogle Scholar
  • 3 Rindi G, Capella C. et al. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.  Q J Nucl Med. 2000;  44 13-21
    PubMedGoogle Scholar
  • 4 Kloeppel G, Anlauf M. et al . Klassifikation und Pathologie der neuroendokrinen Tumoren des Magen-Darm-Traktes und Pankreas.  Der Onkologe. 2004;  10 570-579
    PubMedGoogle Scholar
  • 5 Perry R R, Vinik A I. Clinical review 72: diagnosis and management of functioning islet cell tumors.  J Clin Endocrinol Metab. 1995;  80 2273-2278
    CrossrefPubMedGoogle Scholar
  • 6 Smith S L, Branton S A. et al . Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature.  Surgery. 1998;  124 1050-1055
    CrossrefPubMedGoogle Scholar
  • 7 Smith A P, Doolas A. et al . Rapid resolution of necrolytic migratory erythema after glucagonoma resection.  J Surg Oncol. 1996;  61 306-309
    CrossrefPubMedGoogle Scholar
  • 8 Wermers R A, Fatourechi V. et al . Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors.  Mayo Clin Proc. 1996;  71 1030-1038
    PubMedGoogle Scholar
  • 9 Angeletti S, Corleto V D. et al . Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.  Gut. 1998;  42 792-794
    PubMedGoogle Scholar
  • 10 Friesen S R. Update on the diagnosis and treatment of rare neuroendocrine tumors.  Surg Clin North Am. 1987;  67 379-393
    PubMedGoogle Scholar
  • 11 Plockinger U, Rindi G. et al . Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).  Neuroendocrinology. 2004;  80 394-424
    CrossrefPubMedGoogle Scholar
  • 12 Solcia E, Rindi G. et al . Gastric endocrine cells: types, function and growth.  Regul Pept. 2000;  93 31-35
    CrossrefPubMedGoogle Scholar
  • 13 Solcia E, Rindi G. et al . Morphological, molecular, and prognostic aspects of gastric endocrine tumors.  Microsc Res Tech. 2000;  48 339-348
    CrossrefPubMedGoogle Scholar
  • 14 Kloppel G, Perren A. et al . The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.  Ann N Y Acad Sci. 2004;  1014 13-27
    CrossrefPubMedGoogle Scholar
  • 15 Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification.  Neuroendocrinology. 2004;  80 12-15
    CrossrefPubMedGoogle Scholar
  • 16 Rindi G, Paolotti D. et al . Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors.  Virchows Arch. 2000;  436 217-223
    CrossrefPubMedGoogle Scholar
  • 17 Amthauer H, Ruf J. et al . Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?.  Eur J Nucl Med Mol Imaging. 2004;  31 342-348
    CrossrefPubMedGoogle Scholar
  • 18 Xie S D, Wang L B. et al . Minute gastric carcinoid tumor with regional lymph node metastasis: a case report and review of literature.  World J Gastroenterol. 2004;  10 2461-2463
    PubMedGoogle Scholar
  • 19 Borch K, Ahren B. et al . Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.  Ann Surg. 2005;  242 64-73
    CrossrefPubMedGoogle Scholar
  • 20 Fykse V, Sandvik A K. et al . Treatment of ECL cell carcinoids with octreotide LAR.  Scand J Gastroenterol. 2004;  39 621-628
    CrossrefPubMedGoogle Scholar
  • 21 Delle Fave G, Capurso G. et al . Gastric neuroendocrine tumors.  Neuroendocrinology. 2004;  80 16-19
    CrossrefPubMedGoogle Scholar
  • 22 Norton J A, Melcher M L. et al . Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.  Surgery. 2004;  136 1267-1274
    CrossrefPubMedGoogle Scholar
  • 23 Modlin I M, Kidd M. et al . Current status of gastrointestinal carcinoids.  Gastroenterology. 2005;  128 1717-1751
    CrossrefPubMedGoogle Scholar
  • 24 Mulkeen A, Cha C. Gastric carcinoid.  Curr Opin Oncol. 2005;  17 1-6
    CrossrefPubMedGoogle Scholar
  • 25 Thomas R M, Baybick J H. et al . Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients.  Cancer. 1994;  73 2053-2058
    CrossrefPubMedGoogle Scholar
  • 26 Rindi G, Azzoni C. et al . ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.  Gastroenterology. 1999;  116 532-542
    CrossrefPubMedGoogle Scholar
  • 27 Zimmer T, Scherubl H. et al . Endoscopic ultrasonography of neuroendocrine tumours.  Digestion. 2000;  62 45-50
    CrossrefPubMedGoogle Scholar
  • 28 Jensen R. Zollinger-Ellison Syndrome. Philadelphia; Lippincott Williams & Wilkins 2001
    Google Scholar
  • 29 Goldfinger S. Management and prognosis of the Zollinger-Elllison Syndrome (gastrinoma).  UpToDate. 2000;  8 1
    PubMedGoogle Scholar
  • 30 Li M L, Norton J A. Gastrinoma.  Curr Treat Options Oncol. 2001;  2 337-346
    PubMedGoogle Scholar
  • 31 Lehnert H, Becker W. et al .Neuroendokrine Tumoren des Gastrointestinaltrakts. Stuttgart; Thieme 2003
    Google Scholar
  • 32 McEntee G P, Nagorney D M. et al . Cytoreductive hepatic surgery for neuroendocrine tumors.  Surgery. 1990;  108 1091-1096
    PubMedGoogle Scholar
  • 33 Jaeck D, Oussoultzoglou E. et al . Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery.  World J Surg. 2001;  25 689-692
    CrossrefPubMedGoogle Scholar
  • 34 Evans D B, Skibber J M. et al . Nonfunctioning islet cell carcinoma of the pancreas.  Surgery. 1993;  114 1175-1181: discussion 1181 - 1182
    PubMedGoogle Scholar
  • 35 Pape U F, Bohmig M. et al . Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center.  Ann N Y Acad Sci. 2004;  1014 222-233
    CrossrefPubMedGoogle Scholar
  • 36 Wiedenmann B, Plöckinger U. Neuroendocrine gastroenteropancreatic tumors. Oxford; Oxford University Press 1999
    Google Scholar
  • 37 Pellikka P A, Tajik A J. et al . Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.  Circulation. 1993;  87 1188-1196
    CrossrefPubMedGoogle Scholar
  • 38 Dingerkus H, Voller H. et al . [Endocardial fibrosis in neuroendocrine tumors of the gastroenteropancreatic system].  Dtsch Med Wochenschr. 1994;  119 647-652
    PubMedGoogle Scholar
  • 39 O’Toole D, Ducreux M. et al . Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.  Cancer. 2000;  88 770-776
    CrossrefPubMedGoogle Scholar
  • 40 Aparicio T, Ducreux M. et al . Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.  Eur J Cancer. 2001;  37 1014-1019
    CrossrefPubMedGoogle Scholar
  • 41 Plöckinger U. Systemic therapy for metastatic or residual extrapancreatic endocrine tumors. Philadelphia; Lippincott Williams & Wilkins 2001
    Google Scholar
  • 42 Hejna M, Schmidinger M. et al . The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?.  Ann Oncol. 2002;  13 653-668
    CrossrefPubMedGoogle Scholar
  • 43 Faiss S, Pape U F. et al . Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group.  J Clin Oncol. 2003;  21 2689-2696
    PubMedGoogle Scholar
  • 44 Plockinger U, Dienemann D. et al . Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.  J Clin Endocrinol Metab. 1990;  71 1658-1662
    PubMedGoogle Scholar
  • 45 Detjen K M, Welzel M. et al . Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells.  Gastroenterology. 2000;  118 735-748
    CrossrefPubMedGoogle Scholar
  • 46 Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review.  Digestion. 2000;  62 92-97
    CrossrefPubMedGoogle Scholar
  • 47 Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment.  Anticancer Drugs. 1994;  5 503-519
    PubMedGoogle Scholar
  • 48 Moertel C G, Kvols L K. et al . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.  Cancer. 1991;  68 227-232
    CrossrefPubMedGoogle Scholar
  • 49 Ritzel U, Leonhardt U. et al . Treatment of metastasized midgut carcinoids with dacarbazine.  Am J Gastroenterol. 1995;  90 627-631
    PubMedGoogle Scholar
  • 50 Mitry E, Baudin E. et al . Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.  Br J Cancer. 1999;  81 1351-1355
    CrossrefPubMedGoogle Scholar
  • 51 Oberg K. State of the art and future prospects in the management of neuroendocrine tumors.  Q J Nucl Med. 2000;  44 3-12
    PubMedGoogle Scholar
  • 52 Moertel C G, Hanley J A. et al . Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.  N Engl J Med. 1980;  303 1189-1194
    PubMedGoogle Scholar
  • 53 Ramanathan R K, Cnaan A. et al . Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.  Ann Oncol. 2001;  12 1139-1143
    CrossrefPubMedGoogle Scholar
  • 54 Moertel C G, Lefkopoulo M. et al . Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.  N Engl J Med. 1992;  326 519-523
    PubMedGoogle Scholar
  • 55 Eriksson B, Arnberg H. et al . Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients.  J Intern Med. 1990;  228 103-113
    PubMedGoogle Scholar
  • 56 Cheng P N, Saltz L B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.  Cancer. 1999;  86 944-948
    CrossrefPubMedGoogle Scholar
  • 57 Pavel M E, Baum U. et al . Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.  Int J Gastrointest Cancer. 2005;  35 179-185
    CrossrefPubMedGoogle Scholar
  • 58 von Schrenck T, Howard J M. et al . Prospective study of chemotherapy in patients with metastatic gastrinoma.  Gastroenterology. 1988;  94 1326-1334
    PubMedGoogle Scholar
  • 59 Rivera E, Ajani J A. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.  Am J Clin Oncol. 1998;  21 36-38
    CrossrefPubMedGoogle Scholar
  • 60 Bukowski R M, Tangen C. et al . Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.  J Clin Oncol. 1992;  10 1914-1918
    PubMedGoogle Scholar
  • 61 Bajetta E, Rimassa L. et al . 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.  Cancer. 1998;  83 372-378
    CrossrefPubMedGoogle Scholar
  • 62 Siperstein A E, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases.  World J Surg. 2001;  25 693-696
    CrossrefPubMedGoogle Scholar
  • 63 Berber E, Flesher N. et al . Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.  World J Surg. 2002;  26 985-990
    CrossrefPubMedGoogle Scholar
  • 64 Hellman P, Ladjevardi S. et al . Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors.  World J Surg. 2002;  26 1052-1056
    PubMedGoogle Scholar
  • 65 Frilling A, Malago M. et al . Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patients.  Liver Transpl. 2006;  12 1089-1096
    CrossrefPubMedGoogle Scholar

PD Dr. med. Ursula Plöckinger

Interdisziplinäres Stoffwechsel-Centrum, Medizinische Klinik m. S. Hepatologie und Gastroenterologie

Charité-Universitätsmedizin Berlin · Campus Virchow-Klinikum · Augustenburger Platz 1 · 13353 Berlin

Email: ursula.ploeckinger@charite.de